白细胞介素 6：从关节炎到 CAR-T 细胞疗法再到 COVID-19。
IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
机构信息
Laboratory of Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, Suita City, Osaka, Japan.
出版信息
Int Immunol. 2021 Sep 25;33(10):515-519. doi: 10.1093/intimm/dxab011.
Blockade of IL-6 function by an anti-IL-6 receptor (IL-6R) antibody (tocilizumab, trade name Actemra) has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T-cell therapy. Patients with serious cases of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious cases of COVID-19. In the first part of this short review, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T-cell therapy and COVID-19 is then discussed.
阻断白细胞介素 6（IL-6）受体（IL-6R）的功能的单克隆抗体（托珠单抗，商品名 Actemra）已被证明对治疗包括类风湿关节炎在内的慢性自身免疫性炎症性疾病有效。有趣的是，研究还发现托珠单抗治疗可减轻嵌合抗原受体（CAR）-T 细胞治疗引起的细胞因子风暴。严重的 2019 冠状病毒病（COVID-19）患者表现出细胞因子释放综合征（CRS），这表明托珠单抗可能是治疗严重 COVID-19 的有效药物。在这篇短文的第一部分，描述了托珠单抗对 IL-6 过度产生引起的疾病的治疗效果。接着讨论了 CAR-T 细胞治疗和 COVID-19 引起的 CRS。
Zotero 插件